Preventing infections in immunosuppressed patients.

IF 4.2 Q2 PHARMACOLOGY & PHARMACY

Australian Prescriber Pub Date : 2026-02-01 DOI:10.18773/austprescr.2026.003

Aadith Ashok, Aleece I MacPhail, Michelle L Giles, Bradley J Gardiner

引用次数: 0

Abstract

Immunosuppressed patients are vulnerable to infections which can cause significant mortality and morbidity. A dedicated evaluation, performed prior to immunosuppression where possible, can improve infection-related outcomes for these complex patients. Strategies to reduce infection risk include individualised risk assessment, targeted screening investigations, antimicrobial prophylaxis, vaccination and education to reduce future exposures to infectious pathogens.

查看原文本刊更多论文

预防免疫抑制患者感染。

免疫抑制的患者易受感染，感染可导致显著的死亡率和发病率。在可能的情况下，在免疫抑制之前进行专门的评估，可以改善这些复杂患者的感染相关结果。减少感染风险的战略包括个体化风险评估、有针对性的筛查调查、抗菌素预防、疫苗接种和教育，以减少今后接触传染性病原体的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian Prescriber MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY

CiteScore

3.80

自引率

7.40%

发文量

审稿时长

>12 weeks

期刊介绍： Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online. Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information. As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas. We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.